Neuroscientific Biopharmaceuticals Ltd Net Assets

Latest as of December 2025: AU$16.45 Million AUD ≈ $11.64 Million USD

Neuroscientific Biopharmaceuticals Ltd net assets. Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has net assets worth AU$16.45 Million AUD (≈ $11.64 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$16.66 Million ≈ $11.79 Million USD) and total liabilities (AU$207.87K ≈ $147.08K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Neuroscientific Biopharmaceuticals Ltd net asset momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$16.45 Million
% of Total Assets	98.75%
Annual Growth Rate	72.49%
5-Year Change	15.13%
10-Year Change	N/A
Growth Volatility	207.83

Net Assets of Neuroscientific Biopharmaceuticals Ltd (2016–2025)

Net assets of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Neuroscientific Biopharmaceuticals Ltd's balance sheet to measure how much of total assets are equity-financed.

Annual Net Assets for Neuroscientific Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual net assets of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025. For live market cap and overall valuation, see Neuroscientific Biopharmaceuticals Ltd (NSB) market capitalisation.

Year	Net Assets	Change
2025-06-30	AU$16.81 Million ≈ $11.90 Million	+214.26%
2024-06-30	AU$5.35 Million ≈ $3.79 Million	+13.98%
2023-06-30	AU$4.69 Million ≈ $3.32 Million	-14.96%
2022-06-30	AU$5.52 Million ≈ $3.91 Million	-62.20%
2021-06-30	AU$14.60 Million ≈ $10.33 Million	+300.20%
2020-06-30	AU$3.65 Million ≈ $2.58 Million	-27.89%
2019-06-30	AU$5.06 Million ≈ $3.58 Million	+590.89%
2018-06-30	AU$732.52K ≈ $518.30K	+36.72%
2017-06-30	AU$535.79K ≈ $379.10K	+330.47%
2016-06-30	AU$124.47K ≈ $88.07K	--

Equity Component Analysis

This analysis shows how different components contribute to Neuroscientific Biopharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 1985233800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Neuroscientific Biopharmaceuticals Ltd Net Assets Breakdown (June 2025)

Neuroscientific Biopharmaceuticals Ltd net assets breakdown by equity component as of June 2025.

Component	Amount	Percentage
Common Stock	AU$34.26 Million	203.74%
Other Comprehensive Income	AU$5.84 Million	34.74%
Total Equity	AU$16.81 Million	100.00%

Neuroscientific Biopharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their market capitalization.

Company	Market Cap
Prizma Pres Matbaacilik Yayincilik Sanayi ve Ticaret AS IS:PRZMA	$12.72 Million
Seker Finansal Kiralama AS IS:SEKFK	$12.72 Million
Yong Tai Bhd KLSE:7066	$12.73 Million
FACILITIES BY ADF LS-01 F:ZC8	$12.73 Million
Encorp Bhd KLSE:6076	$12.71 Million
Playtech Plc LSE:PTEC	$12.70 Million
Digital Graphics Incorporation KQ:043360	$12.69 Million
Park Ha Biological Technology Co., Ltd. NASDAQ:BYAH	$12.69 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Neuroscientific Biopharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,350,190 to 16,813,513, a change of 11,463,323 (214.3%).
Net loss of 1,845,513 reduced equity.
Share repurchases of 215,000 reduced equity.
New share issuances of 3,504,000 increased equity.
Other comprehensive income increased equity by 3,968,346.
Other factors increased equity by 6,051,490.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-1.85 Million	-10.98%
Share Repurchases	AU$215.00K	-1.28%
Share Issuances	AU$3.50 Million	+20.84%
Other Comprehensive Income	AU$3.97 Million	+23.6%
Other Changes	AU$6.05 Million	+35.99%
Total Change	AU$-	214.26%

Book Value vs Market Value Analysis

This analysis compares Neuroscientific Biopharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.47x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 31.92x to 0.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-06-30	AU$0.00	AU$0.05	x
2017-06-30	AU$0.01	AU$0.05	x
2018-06-30	AU$0.01	AU$0.05	x
2019-06-30	AU$0.07	AU$0.05	x
2020-06-30	AU$0.05	AU$0.05	x
2021-06-30	AU$0.10	AU$0.05	x
2022-06-30	AU$0.04	AU$0.05	x
2023-06-30	AU$0.03	AU$0.05	x
2024-06-30	AU$0.04	AU$0.05	x
2025-06-30	AU$0.11	AU$0.05	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Neuroscientific Biopharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -10.98%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1111.22%
• Asset Turnover: 0.01x
• Equity Multiplier: 1.01x
Recent ROE (-10.98%) is above the historical average (-60.85%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-82.75%	-88.79%	0.47x	1.98x	AU$-115.45K
2017	-48.74%	-686.70%	0.07x	1.08x	AU$-314.70K
2018	-127.15%	-3225.59%	0.04x	1.10x	AU$-1.00 Million
2019	-32.78%	-4901.18%	0.01x	1.01x	AU$-2.17 Million
2020	-78.62%	-3761.64%	0.02x	1.02x	AU$-3.23 Million
2021	-21.76%	-331.47%	0.06x	1.02x	AU$-4.64 Million
2022	-189.05%	-15244.70%	0.01x	1.40x	AU$-10.99 Million
2023	-22.77%	-21.58%	0.94x	1.13x	AU$-1.54 Million
2024	6.06%	14.66%	0.41x	1.02x	AU$-210.81K
2025	-10.98%	-1111.22%	0.01x	1.01x	AU$-3.53 Million

Industry Comparison

This section compares Neuroscientific Biopharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $22,525,639
Average return on equity (ROE) among peers: -53.87%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Neuroscientific Biopharmaceuticals Ltd (NSB)	AU$16.45 Million	-82.75%	0.01x	$12.71 Million
Adalta Ltd (1AD)	$7.49 Million	-79.00%	0.24x	$3.61 Million
Algorae Pharmaceuticals Ltd (1AI)	$4.03 Million	-48.51%	0.06x	$12.88 Million
ACRUX Ltd (ACR)	$18.25 Million	-43.08%	0.12x	$2.61 Million
Actinogen Medical Ltd (ACW)	$10.89 Million	-48.96%	0.10x	$105.70 Million
Argenica Therapeutics Ltd (AGN)	$8.31 Million	-49.24%	0.09x	$11.82 Million
Arovella Therapeutics Ltd (ALA)	$15.99 Million	-12.83%	0.27x	$43.62 Million
Anatara Lifesciences Ltd (ANR)	$2.86 Million	-117.78%	0.17x	$1.40 Million
Alterity Therapeutics Ltd (ATH)	$10.55 Million	-95.37%	0.26x	$108.75 Million
Amplia Therapeutics Ltd (ATX)	$11.42 Million	-39.44%	0.30x	$31.60 Million
Avecho Biotechnology Ltd (AVE)	$135.47 Million	-4.52%	0.28x	$32.81 Million

About Neuroscientific Biopharmaceuticals Ltd

AU:NSB Australia Biotechnology

Market Cap

$12.71 Million

AU$17.96 Million AUD

Market Cap Rank

#26298 Global

#1177 in Australia

Share Price

AU$0.05

Change (1 day)

+3.85%

52-Week Range

AU$0.05 - AU$0.17

All Time High

AU$0.52